Evidence map›Paper›PMID 25387877›Full record

SynthesisWorld journal of urology2015

Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis.

Arie Carneiro, Andre Deeke Sasse, Andrew Aurel Wagner, Guilherme Peixoto, André Kataguiri, Ary Serpa Neto, Bianca Alves Vieira Bianco, Peter Chang, Antônio Carlos Lima Pompeo, Marcos Tobias-Machado

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in World journal of urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 7 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 7 syntheses or guidelines pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Physical exercise for bone health in men with prostate cancer receiving androgen deprivation therapy: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Pooled it
  4. Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: a systematic literature review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Review
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Shared Decision-Making and Cardiovascular Complications of Androgen Deprivation Therapy: an Educational Initiative for Oncology Team Members in Colorado, USA.Journal of cancer education : the official journal of the American Association for Cancer Education · 2024
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Arie CarneiroDepartment of Urology, Faculdade de Medicina do ABC (ABC Medical School), Av. Príncipe de Gales, 821 - Príncipe de Gales, Santo André, São Paulo, SP, 09060-650, Brazil, arie_carneiro@yahoo.com.br.
Andre Deeke Sasse
Andrew Aurel Wagner
Guilherme Peixoto
André Kataguiri
Ary Serpa Neto
Bianca Alves Vieira Bianco
Peter Chang
Antônio Carlos Lima Pompeo
Marcos Tobias-Machado
Faculdade de Medicina do ABC · BRBeth Israel Deaconess Medical Center · USHadassah Medical Center · ILUniversidade Estadual de Campinas (UNICAMP) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextA recently published meta-analysis of randomized clinical trials (RCT) showed that androgen deprivation therapy (ADT) did not significantly increase cardiovascular mortality in prostate cancer patients. However, cardiovascular morbidity, which can impact quality of life, was not evaluated.

objectiveTo evaluate the risk of cardiovascular morbidity associated with ADT in patients with prostate cancer.

methodsWe conducted a literature search from January 1960 to June 2012. RCT and large cohort studies that evaluated first-line endocrine therapy and ADT longer than 6 months were screened for inclusion.

resultsIn total, 126,898 patients were included in four cohort studies, and 10,760 patients were included in nine RCTs. Analysis of the RCTs showed no differences in the development of acute myocardial infarction (AMI) (OR 1.23; 95 % CI 0.92-1.64; I (2): 0 %) among the patients receiving ADT or not. The analysis of randomized studies that reported other nonfatal cardiovascular events demonstrated a significant increase in such events in the group receiving ADT (OR 1.55; 95 % CI 1.09-2.20; I (2): 0 %). When the large cohort studies were included in the analysis, an increased risk of AMI among men with ADT was found (OR 2.01, 95 % CI 1.90-2.13; I (2): 91,3 %).

conclusionThe use of ADT in prostate cancer patients corresponded with a significant increase in cardiovascular morbidity associated with AMI and with nonfatal events. Therefore, ADT is linked to a significant negative impact on quality of life. Periodic cardiovascular evaluation is required for these patients.

Indexed as

Androgen AntagonistsCardiovascular DiseasesCause of DeathGlobal HealthHumansMaleMorbidityProstatic NeoplasmsRisk FactorsSurvival RateAndrogen Antagonists

Identifiers

PMID25387877
OpenAlexW2054074280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.